Abstract
Immunosuppressive effects of cyclosporin A (CsA) and FK 506 (FK) on peripheral blood lymphocytes were studied in dogs in respect to mixed lymphocyte reaction, proliferative responses to recombinant interleukin-2 (rIL-2), phytohemagglutinin (PHA) and concanavalin-A (Con-A); phenotypes of OKIa1, CD3, CD8 and surface IgM; cytotoxic activity against xenogeneic tumor cells. CsA (2.0 or 5.0 mg/kg, intravenously) or FK (0.16 mg/kg, intramuscularly) was given to mongrel dogs every morning for serial 21 days. The blood concentrations of CsA, measured as trough levels by fluorescence polarization method, ranged from 37 to 350 ng/ml in dogs administered at 2.0 mg/kg and from 170 to 894 ng/ml in dogs administered at 5.0 mg/kg during treatment, respectively. In dogs treated with FK at a dose of 0.16 mg/kg, the drug concentrations in the plasma during treatment ranged from 0.16 to 1.8 ng/ml. Mixed lymphocyte reaction and proliferative responses to rIL-2, PHA and Con-A, which were declined by CsA, were not affected by FK. In contrast, the proportion of OKIa1+ cells was not affected by CsA, whereas FK decreased the proportion of OKIa1+ cells progressively during the course of treatment. Cytotoxic activity was suppressed by both CsA and FK. These results possibly indicate that CsA and FK exert their immunosuppressive effects via different mechanisms.
Similar content being viewed by others
Abbreviations
- APC:
-
antigen presenting cells
- BW:
-
body weight
- CM:
-
complete culture medium
- Con-A:
-
concanavalin-A
- cpm:
-
counts per minute
- CsA:
-
cyclosporin A
- FK:
-
FK 506
- GOT:
-
glutamate oxalacetic transaminase
- GPT:
-
glutamate pyruvate transaminase
- HBSS:
-
Hanks' balanced salt solution
- IFN:
-
interferon
- IL-2:
-
interleukin-2
- LDH:
-
lactate dehydrogenase
- MMC:
-
mitomycin C
- MLR:
-
mixed lymphocyte reaction
- NK:
-
natural killer
- PBL:
-
peripheral blood lymphocytes
- PHA:
-
phytohemag glutinin
- PR:
-
proliferative responses
- rIL-2:
-
recombinant interleukin-2
- SI:
-
stimulation index
- 3H-TdR:
-
tritiated thymidine
References
Caine RY. The initial study of the immunosuppressive effects of 6-mercaptopurine and azathioprine in organ transplantation and a few words on cyclosporin A. World J Surg 1982; 6: 637–40.
Calne RY, White DJG. The use of cyclosporin A in clinical organ grafting. Ann Surg 1982; 196: 330–7.
White DJG, Calne RY. The use of cyclosporin A. Immunosuppression in organ grafting. Immunological Rev 1982; 65: 115–31.
Carpenter CB. Immunosuppression in organ transplantation. New England J of Med 1990; 332: 1224–6.
Nussenblatt RB, Palestine AG, Rook AH, Scher I, Wacker WB, Gery I. Treatment of intraocular inflammatory disease with cyclosporin A. Lancet 1983; 2: 235–8.
Yoshinoya S, Yamamoto K, Mitamura T, Aikawa T, Takeuchi A, Takahashi K, Miyamoto T. Successful treatment of rheumatoid arthritis with low-dose cyclosporine A. Transplant Proc 1988; 20 (3): 243–7.
Feutren G, Papoz L, Assan R, Vialettes B, Karsenty G, Vexiau P, Du Rostu H, Rodier M, Sirmai J, Lallemand A, Bach JF. Cyclosporin increases the rate of length of remission in insulin-dependent diabetes of recent onset. Lancet 1986; 2: 119–24.
Bunjes D, Hardt C, Rollinghoff M, Wagner H. Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2. Eur J Immunol 1981; 11: 657–61.
Andrus L, Lafferty KJ. Inhibition of T-cell activity by cyclosporin A. Scand J Immunol 1982; 15: 449–58.
Palacios R. Concanavalin A triggers T lymphocytes by directly interacting with their receptors for activation. J Immunol 1982; 128: 337–42.
Reem GH, Cook LA, Vilcek J. Gamma interferon synthesis by human thymocytes and T lymphocytes inhibited by cyclosporin A. Science 1983; 221: 63–5.
Kalman VK, Kimpel GR. Cyclosporin A inhibits the production of gamma interferon (IFN gamma), but does not inhibit production of virus-induced IFN alpha/beta. Cell Immunol 1983; 78: 122–9.
Elliott JF, Lin Y, Mizel SB, Bleackley RC, Harnish DG, Paetkau V. Induction of interleukin 2 messnger RNA inhibited by cyclosporin A. Science 1984; 226: 1439–41.
Kronke M, Leonard WJ, Depper JD, Arya SK, Wong-Staal F, Gallo RC, Waldmann TA, Greene WC. Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription. Proc Natl Acad Sci USA 1984; 81: 5214–8.
Granelli-Piperno A, Inaba K, Steinman RM. Stimulation of lymphokine release from T lymphoblasts: requirement for mRNA synthesis and inhibition by cyclosporin A. J Exp Med 1984; 160: 1792–802.
Palacios R. Cyclosporin A inhibits antigen- and lectininduced but not constitutive production of interleukin 3. Eur J Immunol 1985; 15: 204–6.
Siebenlist U, Durand DB, Bressler P, Holbrook NJ, Norris CA, Karmoun M, Kant JA, Crabtree GB. Promoter region of interleukin-2 gene undergoes chromatin structure changes and confers inducibility on chloramphenicol acetyltransferase gene during activation of T cells. Mol Cell Biol 1986; 6: 3042–9.
Nordmann R, Andersen E, Trussardi R, Mazer NA. Kinetics of interleukin 2 mRNA and protein produced in the human T-cell line Jurkat and effect of cyclosporin A. Biochemistry 1989; 28: 1791–7.
Moldwin RL, Lancki DW, Herold KC, Fitch FW. An antigen receptor-driven, interleukin-2-independent pathway for proliferation of murine cytotoxic T lymphocyte clones. J Exp Med 1986; 163: 1566–82.
Laing TJ, Weiss A. Evidence for IL-2 independent proliferation in human T cells. J Immunol 1988; 140: 1056–62.
Kroczek RA, Black CDV, Barbet J, Shevach EM. Mechanism of action of cyclosporin Ain vivo. I. Cyclosporin A fails to inhibit T lymphocyte activation in response to alloantigens. J Immunol 1987; 139: 3597–603.
Pereira GMB, Miller JF, Shevach EM. Mechanism of action of cyclosporine Ain vivo. II. T cell primingin vivo to alloantigen can be mediated by an IL-2-independent cyclosporine A-resistant pathway. J Immunol 1990; 144: 2109–16.
Havele C, Paetkau V. Cyclosporine blocks the activation of antigen-dependent cytotoxic T lymphocytes directly by an IL-2-independent mechanism. J Immunol 1988; 140: 3303–8.
Herold KC, Lancki DW, Moldwin RL, Fitch FW. Immunosuppressive effects of cyclosporin A on cloned T cells. J Immunol 1986; 136: 1315–21.
Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, Kohsaka M, Aoki H, Imanaka H. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characterisitics. J Antibiotics 1987; 40: 1249–55.
Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T, Goto T, Okuhara M, Kohsaka M, Aoki H, Ochiai T. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506in vitro. J Antibiotics 1987; 40: 1256–65.
Todo S, Fung JJ, Starzl TE, Tzakis A, Demetris AJ, Kormos R, Jain A, Alessiani M, Takaya S, Shapiro R. Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg 1990; 212: 296–307.
Yatscoff RW, Copeland KR, Faraci CJ. Abbott TDx monoclonal antibody assay evaluated for measuring cyclosporine in whole blood. Clin Chem 1990; 36: 1969–73.
Takada K, Shibata N, Yoshimura H, Yoshikawa H, Muranishi S. High performance liquid chromatographicdetermination of cyclosporin A in body fluids. Research Communications in Chemical Pathology and Pharmacology 1985; 48: 369–80.
Tamura K, Kobayashi M, Hashimoto K, Kojima K, Nagase K, Iwasaki K, Kaizu T, Tanaka H, Niwa M. A highly sensitive method to assay FK-506 levels in plasma. Transplant Proc 1987; 19(6): 23–9.
Cadoff EM, Venkataramanan R, Krajack A, Jain AS, Fung JJ, Todo S, Starzl TE. Assay of FK 506 in plasma. Transplant Proc 1990; 22(1): 50–1.
Kasaian MT, Biron CA. Effects of cyclosporin A on IL-2 production and lymphocyte proliferation during infection of mice with lymphocyytc choriomeningitis virus. J. Immunol 1990; 144: 299–306.
Glimcher LH, Kim KJ, Green I, Paul WE. Ia antigenbearing B cell tumor lines can present protein antigen and alloantigen in a major histocompatibility complex-restricted fashion to antigen-reactive T cells. J Exp Med 1982; 155: 445–59.
Birmingham JR, Chesnut RW, Kappler JW, Marrack P, Kubo R, Grey HM. Antigen presentation to T cell hybridomas by a machrophage cell line: An inducible function. J Immunol 1982; 128: 1491–2.
Walker EB, Lanier LL, Warner NL. Concomitant induction of the cell surface expression of Ia determinants and accessory cell function by a murine macrophage tumor cell line. J Exp Med 1982; 155: 629–34.
Wong GHW, Clark-Lewis I, Mckimm-Breschkin JL, Harris AW, Schrader JW. Interferon-gamma induces enhanced expression of Ia and H-2 antigens on B lymphoid, macrophage, and myeloid cell lines. J Immunol 1983; 131: 788–93.
Migliorati G, Cannarile L, Herberman RB, Bartocci A, Stanley ER, Riccardi C. Role of interleukin 2 (IL 2) and hemopoietin-1 (H-1) in the generation of mouse natural killer (NK) cells from primitive bone marrow precursors. J Immunol 1987; 138: 3618–25.
Henney CS, Kuribayashi K, Kern DE, Gillis S. Interleukin-2 augments natural killer cell activity. Nature 1981; 291: 335–8.
Santoli D, Trinchieri G, Koprowski H. Cell-mediated cytotoxicity against virus infected target cells in humans. II. Interferon induction and activation of natural killer cells. J Immunol 1978; 121: 532–8.
Kunkl A, Klaus GGB. Selective effects of cyclosporin A on functional B cell subsets in the mouse. J Immunol 1980; 125: 2526–31.
Berger R, Meingassner JG, Knapp W.In vitro effects of cyclosporin A on human B-cell responses. Scand J immunol 1983; 17: 241–9.
Muraguchi A, Butler JL, Kehrl JH, Falkoff RJM, Fauci AS. Selective suppression of an early step in human B cell activation by cyclosporin A. J Exp Med 1983; 158: 690–702.
Gorelick MH, Bishop GA, Haughton G, Pisetsky DS. Cyclosporine inhibition of CH series murine B-cell lymphomas. Cell Immunol 1987; 107: 219–26.
Starzl TE, Marchioro TL, Waddell WR. The reversal of rejection in human renal homografts with subsequent development of homograft tolerance. Surg Gynecol Obstet 1963; 117: 385–95.
Sawada S, Suzuki G, Kawase Y, Takaku F. Novel immunosuppresive agent, KF 506 in vitro effects on the cloned T cell activation. J Immunol 1987; 139: 1797–803.
Zeevi A, Duquesnoy R, Eiras G, Rabinowich H, Todo S, Makowka L, Starzl TE. Immunosuppressive effect of FK-506 onin vitro lymphocyte activation: synergism with cyclosporin A. Transplant Proc 1987; 19(6): 40–4.
Woo Y, Sewell AW, Thomson AW. The influence of FK-506 and low-concentration ciclosporin on human lymphocyte activation antigen expression and blastogenesis: a flow cytometric analysis. Scand J Immunol 1990; 31: 297–304.
Todo S, Ueda Y, Demetris JA, Imventarza O, Nalesnik M, Venkataramanam R, Makowka L, Starzl TE. Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery 1988; 104: 239–49.
Fung JJ, Todo S, Jain A, McCauley J, Alessiani M, Scotti C, Starzl TE. Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc 1990; 22(1): 6–12.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Takaori, K., Nio, Y., Inoue, K. et al. A comparative study on immunosuppressive effects of cyclosporin A and FK 506 on peripheral blood lymphocytes in dogs. Biotherapy 4, 129–137 (1992). https://doi.org/10.1007/BF02171757
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02171757